股本结构
单位：万股
| 公告日期 | 2026-08-06 | 2026-08-06 | 2026-05-07 | 2026-05-05 | 2026-04-17 | 2026-05-05 |
|---|---|---|---|---|---|---|
| 证券总股本 | 13902.34 | 13876.18 | 13577.06 | 12443.26 | 12427.03 | 12423.78 |
| 普通股本 | 13902.34 | 13876.18 | 13577.06 | 12443.26 | 12427.03 | 12423.78 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2026-08-04 | 2026-06-30 | 2026-05-08 | 2026-05-04 | 2026-04-01 | 2026-03-31 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2026-08-06 | 13902.34 | 未披露 | 定期报告 | 2026-08-04 |
| 2026-08-06 | 13876.18 | 未披露 |
更多>>
From March 31, 2026 to June 30, 2026
Exercise of stock options
Vesting of restricted stock units, net of taxes withheld
Issuance of common stock under Employee Stock Purchase Plan
Issuance of common stock in public offering, net of issuance costs
Issuance of common stock upon conversion of convertible notes
|
2026-06-30 |
| 2026-05-07 | 13577.06 | 未披露 |
更多>>
1.Common Stock offered 9,859,155 shares by the company.
2.The underwriters exercised their option to purchase common stock 1,478,873 shares.
|
2026-05-08 |
| 2026-05-05 | 12443.26 | 未披露 | 定期报告 | 2026-05-04 |
| 2026-04-17 | 12427.03 | 未披露 | 定期报告 | 2026-04-01 |
| 2026-05-05 | 12423.78 | 未披露 |
更多>>
From December 31, 2025 to March 31, 2026
Exercise of stock options
Vesting of restricted stock units, net of taxes withheld
|
2026-03-31 |
| 2026-02-26 | 12316.28 | 未披露 | 定期报告 | 2026-02-23 |
| 2026-02-26 | 12294.32 | 未披露 |
更多>>
From December 31, 2024 to December 31, 2025
Exercise of stock options
Vesting of restricted stock units
Shares withheld related to net share settlement of equity awards
Issuance of common stock under Employee Stock Purchase Plan
Induced conversion of convertible notes
|
2025-12-31 |
| 2025-11-05 | 12226.49 | 未披露 | 定期报告 | 2025-11-03 |
| 2025-11-05 | 12211.95 | 未披露 |
更多>>
From June 30, 2025 to September 30, 2025
Exercise of stock options
Vesting of restricted stock units, net of taxes withheld
Shares withheld related to net share settlement of equity awards
Induced conversion of convertible notes
|
2025-09-30 |
| 2025-08-07 | 11965.72 | 未披露 | 定期报告 | 2025-08-05 |
| 2025-08-07 | 11960.36 | 未披露 |
更多>>
From March 31, 2025 to June 30, 2025
Exercise of stock options
Vesting of restricted stock units
Shares withheld related to net share settlement of equity awards
Issuance of common stock under Employee Stock Purchase Plan
|
2025-06-30 |
| 2025-05-06 | 11942.73 | 未披露 | 定期报告 | 2025-05-05 |
| 2025-05-06 | 11922.03 | 未披露 |
更多>>
From December 31, 2024 to March 31, 2025
Exercise of stock options
Vesting of restricted stock units, net of taxes withheld
|
2025-03-31 |
| 2025-04-10 | 11918.77 | 未披露 | 定期报告 | 2025-03-24 |
| 2025-04-10 | 11843.09 | 未披露 | 定期报告 | 2025-02-28 |
| 2025-02-27 | 11841.07 | 未披露 | 定期报告 | 2025-02-26 |
| 2025-02-27 | 11820.91 | 未披露 |
更多>>
From December 31, 2023 to December 31, 2024
Exercise of stock options
Vesting of restricted stock units
Shares withheld related to net share settlement of equity awards
Issuance of common stock under Employee Stock Purchase Plan
Issuance of common stock under at-the-market offering, net of issuance costs
Issuance of common stock in public offering, net of issuance costs
Issuance of common stock in private placement, net of issuance costs
Exercise of warrants, net
Conversion of 2026 Notes
|
2024-12-31 |
| 2024-11-07 | 11801.42 | 未披露 | 定期报告 | 2024-11-05 |
| 2024-11-07 | 11788.86 | 未披露 |
更多>>
From June 30, 2024 to September 30, 2024
Vesting of restricted stock units
Exercise of stock options
|
2024-09-30 |
| 2024-08-09 | 11765.96 | 未披露 | 定期报告 | 2024-08-07 |
| 2024-08-09 | 11752.50 | 未披露 |
更多>>
From March 31, 2024 to June 30, 2024
Exercise of stock options
Vesting of restricted stock units
Issuance of common stock under Employee Stock Purchase Plan
Issuance of common stock in public offering, net of issuance costs
Issuance of common stock in private placement, net of issuance costs
|
2024-06-30 |
| 2024-06-07 | 11612.84 | 未披露 |
更多>>
On June 7, 202,Cytokinetics, Incorporated, issuance and sale of 9,803,922 shares of the Company's common stock, the Underwriters purchased an additional 1,470,588 shares of Common Stock.
|
2024-06-07 |
| 2024-05-24 | 11465.78 | 未披露 |
更多>>
Common stock offered 9,803,922 shares by the company
|
2024-05-28 |
| 2024-05-28 | 10492.90 | 未披露 | 定期报告 | 2024-05-21 |
| 2024-05-10 | 10485.39 | 未披露 | 定期报告 | 2024-05-08 |
| 2024-04-08 | 10477.40 | 未披露 | 定期报告 | 2024-04-01 |
| 2024-05-10 | 10477.40 | 未披露 |
更多>>
From December 31, 2023 to March 31, 2024
Exercise of stock options
Vesting of restricted stock units
Shares withheld related to net share settlement of equity awards
Issuance of common stock under at-the-market offering, net of issuance costs
Exercise of warrants, net
|
2024-03-31 |
| 2024-04-08 | 10457.61 | 未披露 | 定期报告 | 2024-03-26 |
| 2024-04-08 | 10329.34 | 未披露 | 定期报告 | 2024-02-29 |
| 2024-02-28 | 10300.47 | 未披露 | 定期报告 | 2024-02-27 |
| 2024-02-28 | 10163.79 | 未披露 |
更多>>
From December 31, 2022 to December 31, 2023
Exercise of stock options
Shares withheld related to net share settlement of equity awards
Issuance of common stock under Employee Stock Purchase Plan
Issuance of common stock under at-the-market offering, net of issuance costs
Vesting of restricted stock units
|
2023-12-31 |
| 2023-11-03 | 9805.36 | 未披露 | 定期报告 | 2023-11-01 |
| 2023-11-03 | 9625.18 | 未披露 |
更多>>
From June 30, 2023 to September 30, 2023
Exercise of stock options
Vesting of restricted stock units
Issuance of common stock under at-the-market offering, net of issuance costs
|
2023-09-30 |
| 2023-08-03 | 9599.80 | 未披露 | 定期报告 | 2023-08-01 |
| 2023-05-05 | 9564.06 | 未披露 | 定期报告 | 2023-05-02 |
| 2023-05-05 | 9560.93 | 未披露 |
更多>>
From December 31, 2022 to March 31, 2023
Exercise of stock options
Issuance of common stock under restricted stock units
Shares withheld related to net share settlement of equity awards
|
2023-03-31 |
| 2023-04-07 | 9558.88 | 1000.00 | 定期报告 | 2023-03-21 |
| 2023-03-01 | 9516.14 | 未披露 | 定期报告 | 2023-02-27 |
| 2023-03-01 | 9483.40 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
Exercise of warrants
Issuance of common stock under restricted stock units
Induced conversion of convertible notes
Exercise of stock options
Shares withheld related to net share settlement of equity awards
Issuance of common stock under Employee Stock Purchase Plan
|
2022-12-31 |
| 2022-11-04 | 9463.10 | 未披露 | 定期报告 | 2022-11-02 |
| 2022-11-04 | 9457.81 | 未披露 |
更多>>
From June 30, 2022 to September 30, 2022
Exercise of stock options
Induced conversion of convertible notes
Exercise of warrants
|
2022-09-30 |
| 2022-08-05 | 9414.41 | 未披露 | 定期报告 | 2022-08-02 |
| 2022-08-05 | 8591.52 | 未披露 |
更多>>
From March 31, 2022 to June 30, 2022
Exercise of stock options
Vesting of restricted stock units, net of taxes withheld
Issuance of common stock under Employee Stock Purchase Plan
Exercise of warrants
|
2022-06-30 |
| 2022-05-06 | 8565.22 | 未披露 | 定期报告 | 2022-05-04 |
| 2022-05-06 | 8557.70 | 未披露 |
更多>>
From December 31, 2021 to March 31, 2022
Exercise of stock options
Vesting of restricted stock units,net of taxes withheld
|
2022-03-31 |
| 2022-04-08 | 8550.39 | 未披露 | 定期报告 | 2022-03-21 |
| 2022-02-25 | 8485.60 | 未披露 | 定期报告 | 2022-02-22 |
| 2022-02-25 | 8479.95 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Exercise of stock options
Vesting of restricted stock units, net of taxes withheld
Underwritten public offering of common stock, net of discounts, commissions and offering cost
Issuance of common stock upon private placement
Issuance of common stock under Employee Stock Purchase Plan
|
2021-12-31 |
| 2021-11-05 | 8388.30 | 未披露 | 定期报告 | 2021-11-01 |
| 2021-11-05 | 8382.59 | 未披露 |
更多>>
From June 30, 2021 to September 30, 2021
Exercise of stock options
Underwritten public offering of common stock, net of discounts, commissions and offering cost
|
2021-09-30 |
| 2021-08-06 | 8351.27 | 未披露 | 定期报告 | 2021-08-02 |
| 2021-07-23 | 8306.30 | 未披露 |
更多>>
1.The company announced underwritten public offering of 11,500,000 shares of its common stock at a price to the public of $27.50 per share. This includes the exercise in full by the underwriters of their option to purchase 1,500,000 additional shares of common stock.
2.The number of shares of common stock to be outstanding after the offering is based on the number of shares outstanding as of March 31, 2021.
|
2021-07-23 |
| 2021-08-06 | 7190.48 | 未披露 |
更多>>
From March 31, 2021 to June 30, 2021
Exercise of stock options
Issuance of common stock under Employee Stock Purchase Plan
|
2021-06-30 |
| 2021-05-07 | 7173.81 | 未披露 | 定期报告 | 2021-05-04 |
| 2021-05-07 | 7156.30 | 未披露 |
更多>>
From December 31, 2020 to March 31, 2021
Exercise of stock options
Vesting of restricted stock units, net of taxes withheld
|
2021-03-31 |
| 2021-04-07 | 7111.85 | 未披露 | 定期报告 | 2021-03-26 |
| 2021-04-07 | 7153.66 | 未披露 | 定期报告 | 2021-03-22 |
| 2021-02-26 | 7111.06 | 未披露 | 定期报告 | 2021-02-23 |
| 2021-02-26 | 7101.52 | 未披露 |
更多>>
From December 31, 2019 to December 31, 2020
Exercise of stock options
Exercise of warrants
Underwritten public offering of common stock, net of discounts, commissions and offering cost
Issuance of common stock upon private placement
Issuance under Employee Stock Purchase Plan
Vesting of restricted stock units, net of taxes withheld
|
2020-12-31 |
| 2020-11-06 | 7077.90 | 未披露 | 定期报告 | 2020-11-02 |
| 2020-11-06 | 7059.48 | 未披露 |
更多>>
From June 30, 2020 to September 30, 2020
Exercise of stock options
Exercise of warrants
Underwritten public offering of common stock, net of discounts,commissions and offering cost
Issuance of common stock upon private placement
|
2020-09-30 |
| 2020-08-10 | 7050.47 | 未披露 | 定期报告 | 2020-08-03 |
| 2020-07-21 | 6675.05 | 未披露 |
更多>>
1.Common stock offered by the company 7,291,667 shares of common stock.
2.The number of shares of common stock to be outstanding after this offering as stated above is based on 59,458,852 shares of common stock outstanding as of March 31, 2020.
|
2020-07-21 |
| 2020-07-17 | 6200.84 | 未披露 | 定期报告 | 2020-07-16 |
| 2020-08-10 | 5994.21 | 未披露 |
更多>>
From March 31, 2020 to June 30, 2020
Exercise of stock options
Issuance of common stock under Employee Stock Purchase Plan
|
2020-06-30 |
| 2020-05-08 | 5946.95 | 未披露 | 定期报告 | 2020-05-04 |
| 2020-05-08 | 5945.89 | 未披露 |
更多>>
From December 31, 2019 to March 23, 2020
Exercise of stock options
Vesting of restricted stock units, net of taxes withheld
|
2020-03-23 |
| 2020-03-04 | 5945.04 | 未披露 | 定期报告 | 2020-03-02 |
| 2020-03-04 | 5917.21 | 未披露 |
更多>>
from December 31, 2018 to December 31, 2019
Exercise of stock options
Issuance under Employee Stock Purchase Plan
Vesting of restricted stock units, net of taxes withheld
Issuance of common stock under at-the-market offering, net of issuance costs
|
2019-12-31 |
| 2019-11-01 | 5908.19 | 未披露 |
更多>>
from June 30, 2019 to September 30, 2019
Exercise of stock options
Issuance of common stock under at-the-market offering, net of issuance costs
|
2019-09-30 |
| 2019-08-09 | 5867.89 | 未披露 | 定期报告 | 2019-08-01 |
| 2019-08-09 | 5805.65 | 未披露 |
更多>>
from March 31, 2019 to June 30, 2019
Exercise of stock options
Issuance of common stock under at-the-market offering, net of issuance costs
Issuance of common stock under Employee Stock Purchase Plan
|
2019-06-30 |
| 2019-05-09 | 5772.13 | 未披露 | 定期报告 | 2019-04-30 |
| 2019-05-09 | 5545.12 | 未披露 |
更多>>
from December 31, 2018 to March 31, 2019
Exercise of stock options
Vesting of restricted stock units, net of taxes withheld
Issuance under at-the-market offering, net of issuance costs
|
2019-03-31 |
| 2019-04-03 | 5537.31 | 未披露 | 定期报告 | 2019-03-26 |
| 2019-03-07 | 5488.84 | 未披露 | 定期报告 | 2019-03-05 |
| 2019-04-03 | 5472.30 | 未披露 | 定期报告 | 2019-02-15 |
| 2019-03-07 | 5471.79 | 未披露 |
更多>>
from December 31, 2017 to December 31, 2018
Exercise of stock options
Issuance under Employee Stock Purchase Plan
Vesting of restricted stock units, net of taxes withheld
|
2018-12-31 |
| 2018-11-09 | 5471.09 | 未披露 | 定期报告 | 2018-11-05 |
| 2018-11-09 | 5464.15 | 未披露 |
更多>>
from December 31, 2017 to September 30, 2018
Exercise of stock options
Issuance of common stock under Employee Stock Purchase Plan
Vesting of restricted stock units, net of taxes withheld
|
2018-09-30 |
| 2018-08-07 | 5462.80 | 未披露 | 定期报告 | 2018-07-29 |
| 2018-05-10 | 5419.75 | 未披露 | 定期报告 | 2018-04-30 |
| 2018-03-29 | 5400.81 | 未披露 | 定期报告 | 2018-04-03 |
| 2018-03-05 | 5400.81 | 未披露 | 定期报告 | 2018-02-23 |
| 2018-03-05 | 5396.08 | 未披露 |
更多>>
from December 31, 2016 to December 31, 2017
Exercise of stock options
Issuance of common stock under Employee Stock Purchase Plan
Vesting of restricted stock units, net of taxes withheld
Exercise of warrants
Issuance of common stock under secondary offering net of issuance costs of $3,400
Issuance of common stock under CE Offering at net of commission and issuance costs of $992
Issuance of common stock pursuant to Royalty Purchase Agreement
|
2017-12-31 |
| 2017-11-03 | 5388.47 | 未披露 | 定期报告 | 2017-10-27 |
| 2017-11-03 | 5386.26 | 未披露 | 定期报告 | 2017-09-30 |
| 2017-08-04 | 5366.68 | 未披露 | 定期报告 | 2017-07-27 |
| 2017-08-04 | 5345.71 | 未披露 | 定期报告 | 2017-06-30 |
| 2017-05-04 | 4508.32 | 未披露 | 定期报告 | 2017-04-27 |
| 2017-05-04 | 4341.73 | 未披露 | 定期报告 | 2017-03-31 |
| 2017-03-31 | 4324.13 | 未披露 | 定期报告 | 2017-03-27 |
| 2017-03-06 | 4172.95 | 未披露 | 定期报告 | 2017-02-23 |
| 2017-03-06 | 4064.66 | 未披露 |
更多>>
From December 31, 2015 to December 31, 2016
Issuance of common stock upon exercise of stock options at a weighted price of $6.75 per share
Issuance of common stock pursuant to ESPP at a weighted price of $7.08 per share
Issuance of common stock upon vesting of restricted stock units, net of taxes withheld
Issuance of common stock upon exercise of warrants
|
2016-12-31 |
| 2016-12-16 | 4061.56 | 未披露 | 定期报告 | 2016-12-14 |
| 2016-11-03 | 4051.69 | 未披露 | 定期报告 | 2016-09-30 |
| 2016-08-04 | 3970.39 | 未披露 | 定期报告 | 2016-07-28 |
| 2016-08-04 | 3969.75 | 未披露 | 定期报告 | 2016-06-30 |
| 2016-05-05 | 3962.11 | 未披露 | 定期报告 | 2016-04-28 |
| 2016-03-30 | 3960.74 | 未披露 | 定期报告 | 2016-03-28 |
| 2016-03-03 | 3959.28 | 未披露 | 定期报告 | 2016-02-26 |
| 2016-03-03 | 3958.17 | 未披露 |
更多>>
From December 31, 2014 to December 31, 2015
Issuance of common stock upon exercise of stock options at a weighted price of $6.22 per share
Issuance of common stock pursuant to ESPP at a weighted price of $3.24 per share
Issuance of common stock upon exercise of restricted stock units
Issuance of common stock upon exercise of warrants
Issuance of common stock under CE Offering at $7.00-$12.68 per share, net of commission and issuance costs of $205
|
2015-12-31 |
| 2015-11-05 | 3884.73 | 未披露 | 定期报告 | 2015-10-30 |
| 2015-11-05 | 3875.63 | 未披露 | 定期报告 | 2015-09-30 |
| 2015-09-04 | 3875.62 | 未披露 | 定期报告 | 2015-09-02 |
| 2015-08-05 | 3875.03 | 未披露 | 定期报告 | 2015-07-30 |
| 2015-08-05 | 3872.89 | 未披露 | 定期报告 | 2015-06-30 |
| 2015-05-04 | 3871.71 | 未披露 | 定期报告 | 2015-04-28 |
| 2015-05-04 | 3871.69 | 未披露 | 定期报告 | 2015-03-31 |
| 2015-03-30 | 3870.85 | 未披露 | 定期报告 | 2015-03-27 |
| 2015-03-06 | 3867.49 | 未披露 | 定期报告 | 2015-02-27 |
| 2015-03-06 | 3865.97 | 未披露 |
更多>>
from December 31, 2013 to December 31, 2014
Issuance of common stock upon exercise of stock options for cash at $6.00 per share
Issuance of common stock pursuant to ESPP at a weighted price of $3.38 per share
Issuance of common stock upon exercise of restricted stock units
Issuance of common stock upon exercise of warrants
Issuance of common stock to MLV at $6.64-$6.79 per share, net of commission and issuance costs of $74
Issuance of common stock to collaborative partner for $4.90 per share, net of issuance costs of $8
Issuance of common stock pursuant to February 2014 public offerings at $8.00 per share, net of issuance costs of $2,800
|
2014-12-31 |
| 2014-08-07 | 3660.88 | 未披露 | 定期报告 | 2014-06-30 |
| 2014-05-07 | 3660.88 | 未披露 | 定期报告 | 2014-05-02 |
| 2014-05-07 | 3609.01 | 未披露 | 定期报告 | 2014-03-31 |
| 2014-03-07 | 3607.84 | 未披露 | 定期报告 | 2014-02-28 |
| 2014-03-07 | 3068.16 | 未披露 |
更多>>
from December 31, 2012 to December 31, 2013
Issuance of common stock upon exercise of stock options for cash at $4.02-$11.10 per share
Issuance of common stock pursuant to ESPP at a weighted price of $3.66 per share
Issuance of common stock upon exercise of restricted stock units
Issuance of common stock to related party for $7.12 per share, net of issuance costs of $21
Issuance of common stock upon exercise of warrants
Conversion of Series B convertible preferred stock to common stock at $1,000 per share
Fractional shares settlement pursuant to reverse stock split
Issuance of common stock to MLV at $6.50-$6.79 per share, net of commission and issuance costs of $232
|
2013-12-31 |
| 2013-11-06 | 2951.10 | 未披露 | 定期报告 | 2013-11-05 |
| 2013-11-06 | 2950.31 | 未披露 | 定期报告 | 2013-09-30 |
| 2013-08-07 | 2935.25 | 未披露 | 定期报告 | 2013-07-26 |
| 2013-08-07 | 2868.52 | 0.40 |
更多>>
On June 24, 2013, the Company effected a one-for-six reverse stock split of its common stock.
|
2013-06-30 |
| 2013-06-25 | 2730.00 | 未披露 |
更多>>
June 24, 2013, Cytokinetics, Incorporated announced today that it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a one-for-six reverse stock split of its common stock, effective as of 5:00 p.m. Eastern time today.
|
2013-06-25 |
| 2013-05-08 | 14861.42 | 未披露 | 定期报告 | 2013-04-26 |
| 2013-04-02 | 14646.35 | 1.90 | 定期报告 | 2013-03-28 |
| 2013-03-15 | 14446.35 | 未披露 | 定期报告 | 2013-02-28 |
| 2013-03-15 | 14245.75 | 2.30 |
更多>>
from December 31, 2011 to December 31, 2012
Issuance of common stock pursuant to ESPP at a weighted price of $0.72 per share
Issuance of common stock upon exercise of restricted stock units
Issuance of common stock pursuant to June 2012 public offerings at $0.76 per share, net of issuance costs of $2,139
Issuance of Series B convertible preferred stock pursuant to June 2012 public offerings at $760 per share, net of issuance costs of $881
Issuance of common stock to MLV at $1.05-$1.20 per share, net of commission and issuance costs of $89
Conversion of Series A convertible preferred stock to common stock at $1,000 per share
|
2012-12-31 |
| 2012-11-07 | 14241.31 | 2.30 | 定期报告 | 2012-09-30 |
| 2012-08-06 | 13347.88 | 3.11 | 定期报告 | 2012-06-30 |
| 2012-05-04 | 7751.21 | 0.81 | 定期报告 | 2012-03-31 |
| 2012-03-13 | 7637.68 | 未披露 | 定期报告 | 2012-02-29 |
| 2012-03-13 | 7491.57 | 0.81 |
更多>>
from December 31, 2010 to December 31, 2011
Issuance of common stock upon exercise of stock options for cash at $1.00-$1.20 per share
Issuance of common stock pursuant to ESPP at a weighted price of $1.11 per share
Issuance of common stock to Deerfield at $1.50 per share, net of issuance costs of $53
Issuance of common stock to MLV at $1.00-$1.02 per share, net of commission and issuance costs of $160
Issuance of Series A convertible preferred stock to Deerfield at $1,500 per share, net of issuance costs of $81
|
2011-12-31 |
| 2011-08-04 | 7227.98 | 0.81 | 定期报告 | 2011-06-30 |
| 2011-05-06 | 7221.61 | 未披露 | 定期报告 | 2011-04-29 |
| 2011-05-06 | 6691.61 | 未披露 | 定期报告 | 2011-03-31 |
| 2011-03-11 | 6691.01 | 未披露 | 定期报告 | 2011-02-28 |
| 2011-03-11 | 6690.76 | 未披露 |
更多>>
Issuance of common stock upon exercise of stock options for cash at $0.58-$2.00 per share
Issuance of common stock pursuant to ESPP at a weighted price of $1.70 per share
Issuance of common stock upon drawdown of committed equity financing facility at $2.05-$3.15 per share, net of issuance costs of $1
Cancellation of restricted stock
|
2010-12-31 |
| 2010-11-04 | 6587.89 | 未披露 | 定期报告 | 2010-10-29 |
| 2010-11-04 | 6457.20 | 未披露 | 定期报告 | 2010-09-30 |
| 2010-08-04 | 6452.06 | 未披露 | 定期报告 | 2010-07-30 |
| 2010-08-04 | 6451.31 | 未披露 | 定期报告 | 2010-06-30 |
| 2010-05-07 | 6438.94 | 未披露 | 定期报告 | 2010-04-30 |
| 2010-05-07 | 6247.98 | 未披露 | 定期报告 | 2010-03-31 |
From March 31, 2026 to June 30, 2026
Exercise of stock options
Vesting of restricted stock units, net of taxes withheld
Issuance of common stock under Employee Stock Purchase Plan
Issuance of common stock in public offering, net of issuance costs
Issuance of common stock upon conversion of convertible notes
1.Common Stock offered 9,859,155 shares by the company.
2.The underwriters exercised their option to purchase common stock 1,478,873 shares.
From December 31, 2025 to March 31, 2026
Exercise of stock options
Vesting of restricted stock units, net of taxes withheld
From December 31, 2024 to December 31, 2025
Exercise of stock options
Vesting of restricted stock units
Shares withheld related to net share settlement of equity awards
Issuance of common stock under Employee Stock Purchase Plan
Induced conversion of convertible notes
From June 30, 2025 to September 30, 2025
Exercise of stock options
Vesting of restricted stock units, net of taxes withheld
Shares withheld related to net share settlement of equity awards
Induced conversion of convertible notes
From March 31, 2025 to June 30, 2025
Exercise of stock options
Vesting of restricted stock units
Shares withheld related to net share settlement of equity awards
Issuance of common stock under Employee Stock Purchase Plan
From December 31, 2024 to March 31, 2025
Exercise of stock options
Vesting of restricted stock units, net of taxes withheld
From December 31, 2023 to December 31, 2024
Exercise of stock options
Vesting of restricted stock units
Shares withheld related to net share settlement of equity awards
Issuance of common stock under Employee Stock Purchase Plan
Issuance of common stock under at-the-market offering, net of issuance costs
Issuance of common stock in public offering, net of issuance costs
Issuance of common stock in private placement, net of issuance costs
Exercise of warrants, net
Conversion of 2026 Notes
From June 30, 2024 to September 30, 2024
Vesting of restricted stock units
Exercise of stock options
From March 31, 2024 to June 30, 2024
Exercise of stock options
Vesting of restricted stock units
Issuance of common stock under Employee Stock Purchase Plan
Issuance of common stock in public offering, net of issuance costs
Issuance of common stock in private placement, net of issuance costs
On June 7, 202,Cytokinetics, Incorporated, issuance and sale of 9,803,922 shares of the Company's common stock, the Underwriters purchased an additional 1,470,588 shares of Common Stock.
Common stock offered 9,803,922 shares by the company
From December 31, 2023 to March 31, 2024
Exercise of stock options
Vesting of restricted stock units
Shares withheld related to net share settlement of equity awards
Issuance of common stock under at-the-market offering, net of issuance costs
Exercise of warrants, net
From December 31, 2022 to December 31, 2023
Exercise of stock options
Shares withheld related to net share settlement of equity awards
Issuance of common stock under Employee Stock Purchase Plan
Issuance of common stock under at-the-market offering, net of issuance costs
Vesting of restricted stock units
From June 30, 2023 to September 30, 2023
Exercise of stock options
Vesting of restricted stock units
Issuance of common stock under at-the-market offering, net of issuance costs
From December 31, 2022 to March 31, 2023
Exercise of stock options
Issuance of common stock under restricted stock units
Shares withheld related to net share settlement of equity awards
From December 31, 2021 to December 31, 2022
Exercise of warrants
Issuance of common stock under restricted stock units
Induced conversion of convertible notes
Exercise of stock options
Shares withheld related to net share settlement of equity awards
Issuance of common stock under Employee Stock Purchase Plan
From June 30, 2022 to September 30, 2022
Exercise of stock options
Induced conversion of convertible notes
Exercise of warrants
From March 31, 2022 to June 30, 2022
Exercise of stock options
Vesting of restricted stock units, net of taxes withheld
Issuance of common stock under Employee Stock Purchase Plan
Exercise of warrants
From December 31, 2021 to March 31, 2022
Exercise of stock options
Vesting of restricted stock units,net of taxes withheld
From December 31, 2020 to December 31, 2021
Exercise of stock options
Vesting of restricted stock units, net of taxes withheld
Underwritten public offering of common stock, net of discounts, commissions and offering cost
Issuance of common stock upon private placement
Issuance of common stock under Employee Stock Purchase Plan
From June 30, 2021 to September 30, 2021
Exercise of stock options
Underwritten public offering of common stock, net of discounts, commissions and offering cost
1.The company announced underwritten public offering of 11,500,000 shares of its common stock at a price to the public of $27.50 per share. This includes the exercise in full by the underwriters of their option to purchase 1,500,000 additional shares of common stock.
2.The number of shares of common stock to be outstanding after the offering is based on the number of shares outstanding as of March 31, 2021.
From March 31, 2021 to June 30, 2021
Exercise of stock options
Issuance of common stock under Employee Stock Purchase Plan
From December 31, 2020 to March 31, 2021
Exercise of stock options
Vesting of restricted stock units, net of taxes withheld
From December 31, 2019 to December 31, 2020
Exercise of stock options
Exercise of warrants
Underwritten public offering of common stock, net of discounts, commissions and offering cost
Issuance of common stock upon private placement
Issuance under Employee Stock Purchase Plan
Vesting of restricted stock units, net of taxes withheld
From June 30, 2020 to September 30, 2020
Exercise of stock options
Exercise of warrants
Underwritten public offering of common stock, net of discounts,commissions and offering cost
Issuance of common stock upon private placement
1.Common stock offered by the company 7,291,667 shares of common stock.
2.The number of shares of common stock to be outstanding after this offering as stated above is based on 59,458,852 shares of common stock outstanding as of March 31, 2020.
From March 31, 2020 to June 30, 2020
Exercise of stock options
Issuance of common stock under Employee Stock Purchase Plan
From December 31, 2019 to March 23, 2020
Exercise of stock options
Vesting of restricted stock units, net of taxes withheld
from December 31, 2018 to December 31, 2019
Exercise of stock options
Issuance under Employee Stock Purchase Plan
Vesting of restricted stock units, net of taxes withheld
Issuance of common stock under at-the-market offering, net of issuance costs
from June 30, 2019 to September 30, 2019
Exercise of stock options
Issuance of common stock under at-the-market offering, net of issuance costs
from March 31, 2019 to June 30, 2019
Exercise of stock options
Issuance of common stock under at-the-market offering, net of issuance costs
Issuance of common stock under Employee Stock Purchase Plan
from December 31, 2018 to March 31, 2019
Exercise of stock options
Vesting of restricted stock units, net of taxes withheld
Issuance under at-the-market offering, net of issuance costs
from December 31, 2017 to December 31, 2018
Exercise of stock options
Issuance under Employee Stock Purchase Plan
Vesting of restricted stock units, net of taxes withheld
from December 31, 2017 to September 30, 2018
Exercise of stock options
Issuance of common stock under Employee Stock Purchase Plan
Vesting of restricted stock units, net of taxes withheld
from December 31, 2016 to December 31, 2017
Exercise of stock options
Issuance of common stock under Employee Stock Purchase Plan
Vesting of restricted stock units, net of taxes withheld
Exercise of warrants
Issuance of common stock under secondary offering net of issuance costs of $3,400
Issuance of common stock under CE Offering at net of commission and issuance costs of $992
Issuance of common stock pursuant to Royalty Purchase Agreement
From December 31, 2015 to December 31, 2016
Issuance of common stock upon exercise of stock options at a weighted price of $6.75 per share
Issuance of common stock pursuant to ESPP at a weighted price of $7.08 per share
Issuance of common stock upon vesting of restricted stock units, net of taxes withheld
Issuance of common stock upon exercise of warrants
From December 31, 2014 to December 31, 2015
Issuance of common stock upon exercise of stock options at a weighted price of $6.22 per share
Issuance of common stock pursuant to ESPP at a weighted price of $3.24 per share
Issuance of common stock upon exercise of restricted stock units
Issuance of common stock upon exercise of warrants
Issuance of common stock under CE Offering at $7.00-$12.68 per share, net of commission and issuance costs of $205
from December 31, 2013 to December 31, 2014
Issuance of common stock upon exercise of stock options for cash at $6.00 per share
Issuance of common stock pursuant to ESPP at a weighted price of $3.38 per share
Issuance of common stock upon exercise of restricted stock units
Issuance of common stock upon exercise of warrants
Issuance of common stock to MLV at $6.64-$6.79 per share, net of commission and issuance costs of $74
Issuance of common stock to collaborative partner for $4.90 per share, net of issuance costs of $8
Issuance of common stock pursuant to February 2014 public offerings at $8.00 per share, net of issuance costs of $2,800
from December 31, 2012 to December 31, 2013
Issuance of common stock upon exercise of stock options for cash at $4.02-$11.10 per share
Issuance of common stock pursuant to ESPP at a weighted price of $3.66 per share
Issuance of common stock upon exercise of restricted stock units
Issuance of common stock to related party for $7.12 per share, net of issuance costs of $21
Issuance of common stock upon exercise of warrants
Conversion of Series B convertible preferred stock to common stock at $1,000 per share
Fractional shares settlement pursuant to reverse stock split
Issuance of common stock to MLV at $6.50-$6.79 per share, net of commission and issuance costs of $232
On June 24, 2013, the Company effected a one-for-six reverse stock split of its common stock.
June 24, 2013, Cytokinetics, Incorporated announced today that it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a one-for-six reverse stock split of its common stock, effective as of 5:00 p.m. Eastern time today.
from December 31, 2011 to December 31, 2012
Issuance of common stock pursuant to ESPP at a weighted price of $0.72 per share
Issuance of common stock upon exercise of restricted stock units
Issuance of common stock pursuant to June 2012 public offerings at $0.76 per share, net of issuance costs of $2,139
Issuance of Series B convertible preferred stock pursuant to June 2012 public offerings at $760 per share, net of issuance costs of $881
Issuance of common stock to MLV at $1.05-$1.20 per share, net of commission and issuance costs of $89
Conversion of Series A convertible preferred stock to common stock at $1,000 per share
from December 31, 2010 to December 31, 2011
Issuance of common stock upon exercise of stock options for cash at $1.00-$1.20 per share
Issuance of common stock pursuant to ESPP at a weighted price of $1.11 per share
Issuance of common stock to Deerfield at $1.50 per share, net of issuance costs of $53
Issuance of common stock to MLV at $1.00-$1.02 per share, net of commission and issuance costs of $160
Issuance of Series A convertible preferred stock to Deerfield at $1,500 per share, net of issuance costs of $81
Issuance of common stock upon exercise of stock options for cash at $0.58-$2.00 per share
Issuance of common stock pursuant to ESPP at a weighted price of $1.70 per share
Issuance of common stock upon drawdown of committed equity financing facility at $2.05-$3.15 per share, net of issuance costs of $1
Cancellation of restricted stock